jackie-7
26 November 2020

Five minutes with… Jacqueline Mulryne

Amid the unprecedented challenges presented by COVID-19, questions around the use of second medical use (SMU) patents have become increasingly pertinent. On Tuesday December 1, LSPN Connect ’s session: Addressing Second Medical Use Infringement: An Evaluation of Recent SMU Cases will examine a number of key issues relating to this pivotal area of life sciences IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
18 November 2026   A heated dispute over Boehringer’s diabetes drug empagliflozin has ended in a split decision, with the judge drawing a sharp line between what a patent discloses and what can be inferred from it.
In-house counsel
18 November 2026   Conversations at AI & IP Europe in Brussels prove that in-house IP leaders who 'grasp the nettle'—such as Carola Lempke of AstraZeneca—are becoming essential to their company’s rollout of AI, says Tom Phillips.
Biotech
17 November 2026   A US judge tosses an antitrust lawsuit accusing Alexion of using sham patent litigation to delay competition to Soliris, finding that its favourable settlement with a rival undermined the claims.